CN106074578A - A kind of pharmaceutical composition treating acne and application thereof - Google Patents
A kind of pharmaceutical composition treating acne and application thereof Download PDFInfo
- Publication number
- CN106074578A CN106074578A CN201610528134.XA CN201610528134A CN106074578A CN 106074578 A CN106074578 A CN 106074578A CN 201610528134 A CN201610528134 A CN 201610528134A CN 106074578 A CN106074578 A CN 106074578A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- cosmetics
- acne
- drug preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition treating acne and application thereof, the component of following weight ratio combine: asiaticoside: osthole: cryptotanshinone: paeonol: chlorogenic acid=(3 6): (3 6): (2 4): (2 4): (3 6).The pharmaceutical composition of the present invention application in preparing dermal drug preparation or cosmetics, has effect for the treatment of acne, effective, safe and reliable.
Description
Technical field
The present invention relates to field of medicaments, a kind of pharmaceutical composition treating acne and prepare skin preparation and
Application in cosmetics.
Background technology
Acne is to be made by factors such as hypersteatosis, pilosebaceous duct blocking, antibacterial infection and inflammatory reactions
A kind of chronic inflammatory skin become is sick, is apt to occur in teenager, and male's sickness rate is higher than women.This disease occurs mainly in face
Portion, makes skin be subject to infringement in various degree, mainly shows as hoary hair, blackhead, inflamed papules, and pustule etc., if not in time
Treatment, not only can make face uncomfortable, and can cause facial pigmentation, have a strong impact on the beauty of individual, even can be to individual
The mental health of people impacts.
At present, treat acne many employings Western medicine, such as the tretinoin of external, antibiotic, estrogen, tetracycline for oral administration, Archie
Mycin, metronidazole etc., although have certain curative effect, but side effect is big, and be prone to recurrence.In recent years.Also begin on market
The tcm product of increasing treatment acne occurs, and obtains certain curative effect, but still cures the symptoms, not the disease, and acne is the easiest
Recurrent exerbation.
Acne is referred to as in the traditional Chinese medical science that " acne, " whelk ", " winddorn " etc., just retouched it in " The Yellow Emperor's Canon of Internal Medicine "
State " sweating is shown in wet, is raw furuncle and prickly heat ".In terms of differentiation of tcm, ancients are many to be defended admittedly from lung, and interspaces of skin and muscles being loose is invaded by wind heat outward
Attack and set about, till now, along with the traditional Chinese medical science research to acne, propose the most again dissipating blood stasis and clearing away heat method, fat up clearing away heat method etc..
Along with the deep development of Chinese Traditional Medicine, the most only treatment by Chinese herbs acne provides rich experience, improves especially
Broad masses' acceptances to using treatment by Chinese herbs acne.
Summary of the invention
It is an object of the invention to provide a kind of pharmaceutical composition treating acne, its curative effect is obvious.
To achieve these goals, the present invention adopts the following technical scheme that a kind of pharmaceutical composition treating acne, by with
The component of lower weight ratio combines: asiaticoside: osthole: cryptotanshinone: paeonol: chlorogenic acid=(3-6): (3-6):
(2-4)∶(2-4)∶(3-6)。
Preferably, the component of following weight ratio combine: asiaticoside: osthole: cryptotanshinone: paeonol:
Chlorogenic acid=2: 2: 1: 1: 2.
Aforementioned pharmaceutical compositions application in preparing dermal drug preparation or cosmetics.
Described dermal drug preparation is unguentum, spray or gel.
Described dermal drug preparation is with described pharmaceutical composition as effective ingredient, adds the external that other adjuvants prepare
Dosage form.
Described cosmetics are facial film, astringent or gel.
Described facial film, is with described pharmaceutical composition as effective ingredient, adds the external facial film that other adjuvants prepare.
The pharmaceutical composition that the present invention provides has effect for the treatment of acne, effective, safe and reliable.
Accompanying drawing explanation
Fig. 1, Fig. 2, Fig. 3 be respectively rabbit ear photo after experimental example 1 empty group rabbit ear photo of the present invention, negative group are administered,
Rabbit ear photo after the administration of facial film administration group；
Fig. 4, Fig. 5, Fig. 6 are rabbit after experimental example 1 of the present invention empty group rabbit ear histopathologic slide, negative group are administered respectively
Rabbit ear histopathologic slide after ear histopathologic slide, the administration of facial film administration group.
Detailed description of the invention
The present invention is a kind of pharmaceutical composition treating acne, the component of following weight ratio combine: asiaticoside:
Osthole: cryptotanshinone: paeonol: chlorogenic acid=(3-6): (3-6): (2-4): (2-4): (3-6).Preferably, by following
The component of weight ratio combines: asiaticoside: osthole: cryptotanshinone: paeonol: chlorogenic acid=2: 2: 1: 1: 2.
In pharmaceutical composition of the present invention, cryptotanshinone has antibacterial and anti-acne effect, and asiaticoside can promote cicatrix group
Knitting healing, osthole, paeonol can be with antiallergic, and chlorogenic acid can be antibacterial with antiinflammatory, and full side plays good treatment Cuo jointly
Skin ulcer effect.
Chinese medicine composition of the present invention can apply to prepare dermal drug preparation or cosmetics.
Dermal drug preparation can be the exterior-applied formulations such as unguentum, spray or gel, is with described pharmaceutical composition for having
Effect composition, adds the exterior-applied formulation that other adjuvants prepare.Cosmetics can be facial film, astringent or gel etc., is with described medicine
Compositions is effective ingredient, adds what other adjuvants prepared.Such as facial film, is with described pharmaceutical composition as effective ingredient,
Adding the external facial film that other adjuvants prepare, face pack prescription mesostroma is preferably water soluble ingredient.
Below in conjunction with embodiment, the present invention is further illustrated, but the present invention is not limited to this specific examples.
Embodiment 1
[formula] asiaticoside 0.4g, osthole 0.4g, cryptotanshinone 0.2, paeonol 0.2g, chlorogenic acid 0.4g, urine
Bursin 2g, xanthan gum 5g, methyl hydroxybenzoate 1g, hyaluronate sodium 2g, propylene glycol 100g, hexamidine dihydroxy ethyl sulfonate 1g, benzene
Oxyethanol 4g, water adds to 1000g.
Cryptotanshinone propylene glycol, 1. under the conditions of lucifuge, is dissolved completely by [preparation method]；
2. adding water in sawing sheet pot, stirring adds xanthan gum, the cryptotanshinone dissolved with propylene glycol, allantoin, hydroxyl
Benzene methyl is heated to 80-85 DEG C, confirms to dissolve completely；
3. stirring is cooled to 70-65 DEG C, the hyaluronate sodium that addition water dissolution is good；
4. continuing to be cooled to 50-45 DEG C, stirring adds chlorogenic acid, asiaticoside, osthole, phenoxyethanol and with water-soluble
The hexamidine dihydroxy ethyl sulfonate solved；
5. continue to be cooled to 40-35 DEG C, pick test；
6. inspection is qualified, and discharging stands and i.e. obtains facial mask liquid.
Embodiment 2
[formula] asiaticoside 0.6g, osthole 0.3g, cryptotanshinone 0.3g, paeonol 0.3g, chlorogenic acid 0.2g, urine
Bursin 2g, xanthan gum 5g, methyl hydroxybenzoate 1g, hyaluronate sodium 2g, propylene glycol 100g, hexamidine dihydroxy ethyl sulfonate 1g, benzene
Oxyethanol 4g, water adds to 1000g.
Cryptotanshinone propylene glycol, 1. under the conditions of lucifuge, is dissolved completely by [preparation method]；
2. adding water in sawing sheet pot, stirring adds xanthan gum, the cryptotanshinone dissolved with propylene glycol, allantoin, hydroxyl
Benzene methyl is heated to 80-85 DEG C, confirms to dissolve completely；
3. stirring is cooled to 70-65 DEG C, the hyaluronate sodium that addition water dissolution is good；
4. continuing to be cooled to 50-45 DEG C, stirring adds chlorogenic acid, asiaticoside, osthole, phenoxyethanol and with water-soluble
The hexamidine dihydroxy ethyl sulfonate solved；
5. continue to be cooled to 40-35 DEG C, pick test；
6. inspection is qualified, and discharging stands and get final product.
Embodiment 3
[formula] asiaticoside 0.3g, osthole 0.6g, cryptotanshinone 0.1g, paeonol 0.3g, chlorogenic acid 0.3g, urine
Bursin 2.5g, xanthan gum 15g, methyl hydroxybenzoate 1g, hyaluronate sodium 8g, propylene glycol 150g, hexamidine dihydroxy ethyl sulfonate
1.5g, phenoxyethanol 4g, water adds to 1000g.
Cryptotanshinone propylene glycol, 1. under the conditions of lucifuge, is dissolved completely by [preparation method]；
2. adding water in sawing sheet pot, stirring adds xanthan gum, the cryptotanshinone dissolved with propylene glycol, allantoin, hydroxyl
Benzene methyl is heated to 80-85 DEG C, confirms to dissolve completely；
3. stirring is cooled to 70-65 DEG C, the hyaluronate sodium that addition water dissolution is good；
4. continuing to be cooled to 50-45 DEG C, stirring adds chlorogenic acid, asiaticoside, osthole, phenoxyethanol and with water-soluble
The hexamidine dihydroxy ethyl sulfonate solved；
5. continue to be cooled to 40-35 DEG C, pick test；
6. inspection is qualified, and discharging stands and get final product.
Embodiment 4
[formula] asiaticoside 0.5g, osthole 0.4g, cryptotanshinone 0.18g, paeonol 0.25g, chlorogenic acid 0.4g,
Allantoin 2g, xanthan gum 5g, methyl hydroxybenzoate 1g, hyaluronate sodium 2g, propylene glycol 100g, hexamidine dihydroxy ethyl sulfonate 1g,
Phenoxyethanol 4g, water adds to 1000g.
Cryptotanshinone propylene glycol, 1. under the conditions of lucifuge, is dissolved completely by [preparation method]；
2. adding water in sawing sheet pot, stirring adds xanthan gum, the cryptotanshinone dissolved with propylene glycol, allantoin, hydroxyl
Benzene methyl is heated to 80-85 DEG C, confirms to dissolve completely；
3. stirring is cooled to 70-65 DEG C, the hyaluronate sodium that addition water dissolution is good；
4. continuing to be cooled to 50-45 DEG C, stirring adds chlorogenic acid, asiaticoside, osthole, phenoxyethanol and with water-soluble
The hexamidine dihydroxy ethyl sulfonate solved；
5. continue to be cooled to 40-35 DEG C, pick test；
6. inspection is qualified, and discharging stands and get final product.
Experimental example 1
1 material
1.1 animals: new zealand rabbit, regular grade, 2～2.5kg, male, Nanfang Medical Univ's animal center provide, experiment
Animal quality quality certification numbering No44002100007496, credit number SCXK (Guangdong) 2011-0015.
1.2 reagents: tested material, facial mask liquid as prepared by the embodiment of the present invention 1.
2 methods and result
2.1 packets, modeling and administration
Modeling: rabbit is randomly divided into 3 groups, blank group 3, negative group 3, facial film administration group 3.Except blank group is not done
Outside any process, remaining two groups in the range of every rabbit ear medial surface auditive catheter opening part about 2cm*2cm every day be coated with 8% coal tar
Solution 1 time, each 0.5～1.0ml, continuous three thoughtful grow preferable acne.
It is administered: negative group smears normal saline, continuously in every rabbit ear medial surface auditive catheter opening part about 2cm*2cm scope
3 weeks, each 1～2ml；Facial film administration group smears outer painting originally in every rabbit ear medial surface auditive catheter opening part about 2cm*2cm scope
Facial mask liquid prepared by inventive embodiments 1, continuous 3 weeks, each 1～2ml.
Carried out perusal at the 22nd day, after record, rabbit is put to death, cut off rabbit ear chilling treatment.
The preparation of auricle: use 5mm card punch to prepare auricle in the punching of coating position.After 10% formaldehyde is fixing, ethanol takes off
Water, by paraffin embedding, serial section, slice thickness 4 μm, HE dyes, dehydration, mounting.
3. result
3.1 ordinary circumstance
Each treated animal upgrowth situation is good, no abnormality seen obesity or weight loss, and defecation is normal, and diet is normal, spirit shape
Condition is good.
3.2 rabbit ear surface observations
(1) the blank group rabbit ear is soft, poor, and blood vessel is clear, and follicular orifice is intensive, marshalling, has no desquamation, such as Fig. 1.
(2) the negative group rabbit ear is compared with blank group, has slight desquamation, black acne dense arrangement, major part follicular orifice
Still having keratotic plug, rough surface, such as Fig. 2.
(3) there is not desquamation in the facial film administration group rabbit ear, still has very small amount white acne to occur, follicular orifice keratotic plug stays after coming off
More lower depressions, such as Fig. 3.
3.3 pathological tissues are observed
(1) blank group epidermis is relatively thin, and the handing-over of hair follicle, epidermis, corium is clear.See Fig. 4.
(2) negative group epidermal hyperkeratosis, irregular hypertrophy, follicular orifice expands similar funnel-form, extends to sebum, hair follicle
Mouthful full keratinization material and expand prominent, it is seen that inflammatory cell infiltration.See Fig. 5.
(3) facial film administration group epidermis thickens reduction, and hair follicle gyalectiform structure disappears or weakens, dermal inflammation Leukopenia, hair
Capsule, almost without keratinization material, is shown in Fig. 6.
3.4 conclusion
Follicular hyperkeratosis is the important step of pathogenesis of acne mechanism, therefore when evaluating curative effect of medication, the keratinization of hair follicle
Degree is also considered as one of standard judging its curative effect, and negative group is compared with blank group, it is seen that negative group follicular keratosis is abnormal,
Follicular orifice expands such as gyalectiform, and funnel is internal is full of keratinization material, illustrates that rabbit ear modeling success and normal saline do not have therapeutical effect,
Rabbit ear acne can not be repaired automatically.After drug administration of the present invention, it is seen that after medication follicular keratosis abnormal be improved significantly, medicine
There is effect for the treatment of acne.
Claims (7)
1. treat a pharmaceutical composition for acne, the component of following weight ratio combine: asiaticoside: osthole:
Cryptotanshinone: paeonol: chlorogenic acid=(3-6): (3-6): (2-4): (2-4): (3-6).
The pharmaceutical composition for the treatment of acne the most according to claim 1, it is characterised in that by the component group of following weight ratio
Conjunction forms: asiaticoside: osthole: cryptotanshinone: paeonol: chlorogenic acid=2: 2: 1: 1: 2.
3. the application in preparing dermal drug preparation or cosmetics of the pharmaceutical composition described in claim 1 or 2.
The most according to claim 3, pharmaceutical composition application in preparing dermal drug preparation or cosmetics, its feature exists
In: described dermal drug preparation is unguentum, spray or gel.
The most according to claim 4, pharmaceutical composition application in preparing dermal drug preparation or cosmetics, its feature exists
In: described dermal drug preparation is with described pharmaceutical composition as effective ingredient, adds the exterior-applied formulation that other adjuvants prepare.
The most according to claim 3, pharmaceutical composition application in preparing dermal drug preparation or cosmetics, its feature exists
In: described cosmetics are facial film, astringent or gel.
The most according to claim 6, pharmaceutical composition application in preparing dermal drug preparation or cosmetics, its feature exists
In: described facial film, is with described pharmaceutical composition as effective ingredient, adds the external facial film that other adjuvants prepare.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610528134.XA CN106074578B (en) | 2016-07-06 | 2016-07-06 | A kind of pharmaceutical composition and its application for treating acne |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610528134.XA CN106074578B (en) | 2016-07-06 | 2016-07-06 | A kind of pharmaceutical composition and its application for treating acne |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106074578A true CN106074578A (en) | 2016-11-09 |
| CN106074578B CN106074578B (en) | 2019-03-05 |
Family
ID=57212458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610528134.XA Expired - Fee Related CN106074578B (en) | 2016-07-06 | 2016-07-06 | A kind of pharmaceutical composition and its application for treating acne |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106074578B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115252447A (en) * | 2022-09-14 | 2022-11-01 | 苏州罗德医药有限公司 | Compound acne-removing composition and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530496A (en) * | 2009-01-08 | 2009-09-16 | 孙海生 | External-use Chinese patent medicine aqua for treating acne |
| CN102106882A (en) * | 2009-12-28 | 2011-06-29 | 重庆华邦制药股份有限公司 | Natural compound medicine for treating acnes and scars |
| CN102233006A (en) * | 2011-03-01 | 2011-11-09 | 广州市娇兰化妆品有限公司 | Compound Chinese medicinal extract for treating acne and application thereof |
-
2016
- 2016-07-06 CN CN201610528134.XA patent/CN106074578B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530496A (en) * | 2009-01-08 | 2009-09-16 | 孙海生 | External-use Chinese patent medicine aqua for treating acne |
| CN102106882A (en) * | 2009-12-28 | 2011-06-29 | 重庆华邦制药股份有限公司 | Natural compound medicine for treating acnes and scars |
| CN102233006A (en) * | 2011-03-01 | 2011-11-09 | 广州市娇兰化妆品有限公司 | Compound Chinese medicinal extract for treating acne and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 候刚健等: "牡丹皮酊的制备及临床治疗寻常型痤疮疗效观察", 《辽宁中医药大学学报》 * |
| 兰水中等主编: "《常见病中成药新用法》", 31 January 2014, 人民军医出版社 * |
| 汤迎爽等: "复方参金凝胶质量控制标准研究", 《中华中医药学刊》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115252447A (en) * | 2022-09-14 | 2022-11-01 | 苏州罗德医药有限公司 | Compound acne-removing composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106074578B (en) | 2019-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105943666B (en) | Composition for nursing sensitive skin of infant and preparation method thereof | |
| US11045503B2 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis | |
| CN102764256A (en) | Ointment for treating acnes | |
| CN106074578B (en) | A kind of pharmaceutical composition and its application for treating acne | |
| EP3884942B1 (en) | Use of bulleyaconitine a for treating skin disorders | |
| CN105726586A (en) | External preparation of ginkgo biloba extract and preparation method and application of external preparation | |
| CN101711807B (en) | Antiphlogistic and antibiotic ointment | |
| CN103721138B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating rosacea | |
| CN105963367A (en) | Preoperative nursing gel for anorectal surgery and preparation method of gel | |
| CN109453275A (en) | A kind of complex external medicine and preparation method thereof for treating chloasma | |
| CN104474528A (en) | Medicine used for drainage detoxification | |
| WO2015059572A1 (en) | A method for topically treating actinic keratosis with ingenol 3-(3,5-diethylisoxazole-4-carboxylate) | |
| CN104367906A (en) | Medicine for treating burns and scalds, acne rosacea and acnes and preparation method thereof | |
| CN114712376A (en) | Application of pulsatilla chinensis saponin B4 in preparation of external-use medicine for treating psoriasis | |
| CN103751613B (en) | A kind of Chinese medicinal liniment treating wind heat blood-dryness type seborrheic dermatitis | |
| CN113144115A (en) | Traditional Chinese medicine composition for treating verruca vulgaris and application thereof | |
| CN102106883B (en) | Medicinal composition containing asiaticoside and tretinoin | |
| CN104546880A (en) | External preparation for treating facial seborrheic dermatitis | |
| CN106560178A (en) | Compositions containing magnolol, honokiol and nonsteroidal antiinflammatory drug, and applications thereof | |
| CN114377054B (en) | Use of cyclocarya paliurus leaves or extracts thereof in preparation of drugs or cosmetics for preventing and/or treating acne | |
| CN116570700B (en) | Traditional Chinese medicine preparation with antibacterial, anti-inflammatory and acne removing effects and application thereof | |
| CN112773786B (en) | Application of icariin in preparation of psoriasis treatment medicine | |
| CN106039315A (en) | Pregnant vulva eczema nursing drug and preparation method thereof | |
| CN107496708B (en) | Traditional Chinese medicine mask for treating acne and preparation method thereof | |
| CN114796176A (en) | A pharmaceutical composition for treating dermatoses, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201210 Address after: Room 509, No.7, Shuangshan Avenue, Nansha District, Guangzhou City, Guangdong Province 510000 (office only) Patentee after: Guangzhou Chenlong Biotechnology Co.,Ltd. Address before: 510515 No. 1023-1063 Shatainan Road, Baiyun District, Guangzhou City, Guangdong Province Patentee before: SOUTHERN MEDICAL University |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190305 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |